Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: API Import to Russia (September 2018)

Friday, November 16, 2018

Between January and September 2018, Russia imported 68.9 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 26.8% higher than that of the same period of 2017. In physical terms, the dynamics are -8.5%, and the imported volume is 8,300 tons.

By the end of the period, the dynamics of the import of both pharmacopoeial and technical APIs have nearly become equal, with +26.9% and +23.9%, respectively. However, the dynamics of the technical API import in physical terms is decreasing, while being ahead of the average market dynamics (-14.5%.)

Between January and September 2018, 17 new companies entered the list of the companies importing pharmacopoeial APIs to Russia, while the number of the new companies for the technical API import list is only 2. The total number of the companies importing pharmacopoeial and technical APIs to Russia are 474 and 89, respectively. The product list for pharmacopoeial APIs included 28 new names out of 625, while that for technical APIs lost 22 names out of 115.

Despite the technical API import volumes falling, there are positive moments. Indian Arene Lifesciences is the absolute leader, with nearly 32% of the total technical API import in monetary terms. In 2018, it imported three products to Russia. Pharmasyntez is their only consumer, anti-HIV generics Simanod (Atazanavir) and Calidavir (Lopinavir+Ritonavir) are produced on its facilities in Irkutsk.

Dynamics of pharmacopoeial and technical API import to Russia, customs clearance prices (2015 – 2017, January – September 2018), bln RUB